Breast Cancer Dataset Sample Clauses

Breast Cancer Dataset. The Breast dataset1 is a comprehensive dataset that contains nearly all the PLCO study data available for breast cancer incidence and mortality analyses. For many women the trial documents multiple breast cancers, however, this file only has data on the earliest breast cancer diagnosed in the trial. The dataset contains one record for each of the approximately 78,000 women in the PLCO trial. Dataset Name PLCO Breast dataset Owner organization NIH National Cancer Institute Dataset description Dataset description (informal meta-data) The Breast dataset is a comprehensive dataset that contains nearly all the PLCO study data available for breast cancer incidence and mortality analyses. For many women the trial documents multiple breast cancers, however, this file only has data on the earliest breast cancer diagnosed in the trial. The dataset contains one record for each of the approximately 78,000 women in the PLCO trial. It is a dataset that was already available when the BOUNCE project started. The data will be explored for their potential to be used in the project for building an in-silico model for resilience prediction. Formal Meta- data There is a detailed Data Dictionary available at xxxxx://xxxx.xxxxxx.xxx/files/download/kwftwu0fr9/breast2nd.dictionary. nov18.d070819.pdf Standards No specific standards have been followed. 1 xxxxx://xxxxxxxx.xxx.xxx.xxx/cdas/datasets/plco/19/ Origin NIH National Cancer Institute Language In English language Size 200 KB Variety Fully structured dataset Type Numeric Format CSV file Velocity Data are included in one CSV file Storage Data are currently stored in NIH but a copy is also available at the BOUNCE data infrastructure Quality High quality data, with not many missing values. In addition a quality and consistency check has already been performed by the owning institution. Example xxxxx://xxxx.xxxxxx.xxx/datasets/plco/19/ Data sharing and ownership Availability The whole dataset is available to the public through their download site. However a data request is necessary and a data transfer agreement should be signed. Through the BOUNCE platform, the data will not be made available to external entities. Availability after the end of the project The data will be available after the end of the BOUNCE project both internally in the BOUNCE platform for consortium members and through the original dataset’s website. Sharing mechanisms Data are accessible through the original data web site. Within BOUNCE data are accessible t...
Sample 1
AutoNDA by SimpleDocs
Breast Cancer Dataset. The Breast dataset5 is a comprehensive dataset that contains nearly all the PLCO study data available for breast cancer incidence and mortality analyses. For many women the trial documents multiple breast cancers, however, this file only has data on the earliest breast cancer diagnosed in the trial. The dataset contains one record for each of the approximately 78,000 women in the PLCO trial. Table 8 presents the various fields of the dataset. Table 8. Data fields available for the Breast Cancer dataset Data Field Description IDENTIFIERS 5 xxxxx://xxxxxxxx.xxx.xxx.xxx/cdas/datasets/plco/19/ PLCO ID PLCO ID Char Build Masterfile build, used to identify the version of the database. Char,30
Sample 1

Related to Breast Cancer Dataset

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Tuberculosis Examination The examination shall consist of an approved intradermal tuberculosis test, which, if positive, shall be followed by an X-ray of the lungs. Nothing in Sections 5163 to 5163.2, inclusive, shall prevent the governing body of any city or county, upon recommendation of the local health officer, from establishing a rule requiring a more extensive or more frequent examination than required by Section 5163 and this section. § 5163.2. Technician taking X-ray film; Interpretation of X-ray The X-ray film may be taken by a competent and qualified X-ray technician if the X-ray film is subsequently interpreted by a licensed physician and surgeon.

  • Preferred Provider - Prescription Drugs The Board shall provide, through the Xxxxx County Council of Governments, a preferred provider drug program that, if the employee chooses to utilize, will include the following:

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Infectious Disease Where an employee produces documentary evidence that:

  • Insulin Insulin will be treated as a prescription drug subject to a separate copay for each type prescribed.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

Time is Money Join Law Insider Premium to draft better contracts faster.